Indirubin-3′-oxime (Synonyms: IDR3O; I3O)

Name: Indirubin-3′-oxime
Brand: MedChemExpress
SKU: HY-139254
Rating: 4.5 (1 reviews)

Cat. No.: HY-139254 Purity: 99.10%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Indirubin-3′-oxime (IDR3O), a synthetic derivative of indirubin, is a potent inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3β (GSK3β). Indirubin-3′-oxime directly inhibits the activity of all three isoforms of JNK (JNK1, JNK2, and JNK3), with IC₅₀s of 0.8 μM, 1.4 μM, and 1.0 μM, respectively. Indirubin-3′-oxime can enhance height growth via activation of Wnt/β-catenin signaling in chondrocytes.

For research use only. We do not sell to patients.

Indirubin-3′-oxime Chemical Structure

CAS No. : 667463-82-3

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All CDK Isoform Specific Products:

View All Isoforms

CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85 CDK10 CDK15 CDK17 CDK18 CDK20 PITSLRE

View All GSK-3 Isoform Specific Products:

View All Isoforms

GSK-3 GSK-3α GSK-3β

View All JNK Isoform Specific Products:

View All Isoforms

JNK1 JNK2 JNK3 JNK

View All Wnt Isoform Specific Products:

View All Isoforms

Wnt1 Wnt3 Wnt5 Wnt7

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]^[2]^[3]

JNK1

0.8 μM (IC₅₀)

JNK2

1.4 μM (IC₅₀)

JNK3

1 μM (IC₅₀)

GSK-3β

CDK

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	27 μM Compound: 5a	Antiproliferative activity against apoptosis resistant human A549 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis resistant human A549 cells after 72 hrs by MTT assay	[PMID: 26883150]
A549	IC₅₀	4.04 μM Compound: IO	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 38295524]
A549	IC₅₀	4.17 μM Compound: IDM	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay	[PMID: 37832229]
A549	IC₅₀	5.82 μM Compound: IM	Growth inhibition of human A549 cells incubated for 3 days by SRB assay Growth inhibition of human A549 cells incubated for 3 days by SRB assay	[PMID: 28625363]
A549	IC₅₀	6.06 μM Compound: IDM	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay	[PMID: 37832229]
A549	IC₅₀	8.21 μM Compound: IDM	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay	[PMID: 37832229]
B16-F10	IC₅₀	5.4 μM Compound: 5a	Antiproliferative activity against apoptosis sensitive mouse B16F10 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis sensitive mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 26883150]
HCT-116	IC₅₀	0.83 μM Compound: IDM	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay	[PMID: 37832229]
HCT-116	IC₅₀	1.37 μM Compound: IDM	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay	[PMID: 37832229]
HCT-116	IC₅₀	3.88 μM Compound: IDM	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay	[PMID: 37832229]
HCT-116	IC₅₀	4.22 μM Compound: IO	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 38295524]
HL-60	GI₅₀	36.6 μM Compound: 18	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured after 3 days by trypan blue staining based inverted microscope method Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured after 3 days by trypan blue staining based inverted microscope method	[PMID: 34161865]
HUVEC	IC₅₀	0.36 μM Compound: 18	Antiproliferative activity against HUVEC cells assessed as cell growth inhibition measured after 3 days by [3H]-thymidine incorporation assay Antiproliferative activity against HUVEC cells assessed as cell growth inhibition measured after 3 days by [3H]-thymidine incorporation assay	[PMID: 34161865]
HepG2	IC₅₀	15 μM Compound: 2	Antiproliferative activity against human HepG2 cells assessed cell survival after 24 hrs by alamarBlue assay Antiproliferative activity against human HepG2 cells assessed cell survival after 24 hrs by alamarBlue assay	[PMID: 25765906]
HepG2	IC₅₀	5.66 μM Compound: IO	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 38295524]
Hs 683	IC₅₀	6 μM Compound: 5a	Antiproliferative activity against apoptosis sensitive human Hs683 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis sensitive human Hs683 cells after 72 hrs by MTT assay	[PMID: 26883150]
HuCCT-1	IC₅₀	5 μM Compound: 18	Antiproliferative activity against human HuCCT-1 cells assessed as cell growth inhibition measured upto 72 hrs by CCK-8 assay Antiproliferative activity against human HuCCT-1 cells assessed as cell growth inhibition measured upto 72 hrs by CCK-8 assay	[PMID: 34161865]
KB	IC₅₀	5.34 μM Compound: IM	Growth inhibition of human KB cells incubated for 3 days by SRB assay Growth inhibition of human KB cells incubated for 3 days by SRB assay	[PMID: 28625363]
LXFL 529	IC₅₀	3 μM Compound: 18	Cytotoxicity against human LXFL 529 cells assessed as cell growth inhibition measured after 3 days by SRB assay Cytotoxicity against human LXFL 529 cells assessed as cell growth inhibition measured after 3 days by SRB assay	[PMID: 34161865]
LoVo	IC₅₀	8.9 μM Compound: 5a	Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay	[PMID: 26883150]
MCF7	IC₅₀	1.41 μM Compound: IDM	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay	[PMID: 37832229]
MCF7	IC₅₀	2.33 μM Compound: IDM	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay	[PMID: 37832229]
MCF7	IC₅₀	3.3 μM Compound: 18	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 3 days by SRB assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 3 days by SRB assay	[PMID: 34161865]
MCF7	IC₅₀	4.1 μM Compound: IDM	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay	[PMID: 37832229]
MCF7	IC₅₀	6.81 μM Compound: IM	Growth inhibition of human MCF7 cells incubated for 3 days by SRB assay Growth inhibition of human MCF7 cells incubated for 3 days by SRB assay	[PMID: 28625363]
MCF7	IC₅₀	9.2 μM Compound: 5a	Antiproliferative activity against apoptosis sensitive human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis sensitive human MCF7 cells after 72 hrs by MTT assay	[PMID: 26883150]
MDA-MB-231	IC₅₀	5.16 μM Compound: IO	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 38295524]
MDA-MB-231	IC₅₀	7.59 μM Compound: IM	Growth inhibition of human MDA-MB-231 cells incubated for 3 days by SRB assay Growth inhibition of human MDA-MB-231 cells incubated for 3 days by SRB assay	[PMID: 28625363]
MV4-11	IC₅₀	1.69 μM Compound: IDM	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay	[PMID: 37832229]
MV4-11	IC₅₀	2.36 μM Compound: IDM	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay	[PMID: 37832229]
MV4-11	IC₅₀	30 nM Compound: 18	Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition measured after 72 hrs by tetrazolium staining based WST-8 assay Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition measured after 72 hrs by tetrazolium staining based WST-8 assay	[PMID: 34161865]
MV4-11	IC₅₀	6.01 μM Compound: IDM	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay	[PMID: 37832229]
NCI-H23	IC₅₀	11.25 μM Compound: Indirubin-3'-oxime	Cytotoxicity against human NCI-H23 cells by colorimetric method Cytotoxicity against human NCI-H23 cells by colorimetric method	[PMID: 32916298]
NCM460	IC₅₀	13.13 μM Compound: IDM	Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay	[PMID: 37832229]
NCM460	IC₅₀	20.18 μM Compound: IDM	Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay	[PMID: 37832229]
NCM460	IC₅₀	21.13 μM Compound: IDM	Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay	[PMID: 37832229]
Oocyte	IC₅₀	0.18 μM Compound: 18	Inhibition of starfish oocyte CDK1/Cyclin B using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by scintillation counter analysis Inhibition of starfish oocyte CDK1/Cyclin B using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by scintillation counter analysis	[PMID: 34161865]
PC-3	IC₅₀	15.8 μM Compound: Indirubin-3'-oxime	Cytotoxicity against human PC3 cells by colorimetric method Cytotoxicity against human PC3 cells by colorimetric method	[PMID: 32916298]
PC-3	IC₅₀	24.3 μM Compound: 5a	Antiproliferative activity against apoptosis sensitive human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis sensitive human PC3 cells after 72 hrs by MTT assay	[PMID: 26883150]
SK-MEL-28	IC₅₀	26.6 μM Compound: 5a	Antiproliferative activity against apoptosis resistant human SK-MEL-28 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis resistant human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 26883150]
SW-620	IC₅₀	13.5 μM Compound: Indirubin-3'-oxime	Cytotoxicity against human SW620 cells by colorimetric method Cytotoxicity against human SW620 cells by colorimetric method	[PMID: 32916298]
U-373MG ATCC	IC₅₀	18 μM Compound: 5a	Antiproliferative activity against apoptosis resistant human U373 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis resistant human U373 cells after 72 hrs by MTT assay	[PMID: 26883150]

In Vitro

In cerebellar granule neurons (CGNs), Indirubin-3′-oxime blocks c-Jun phosphorylation induced by potassium withdrawal and prevented CGNs from apoptosis in a dose dependent manner^[1].
Indirubin-3′-oxime (IDR3O) (PC12 cells; 10 μM) significantly prevent 6OHDA-induced decrease of nuclear localized MEF2D expression^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Indirubin-3′-oxime (0.05 or 0.5 mg/kg; i.p.; daily for 2 or 10 weeks) enhances tibial longitudinal growth in mice without adverse changes in bone thickness parameters^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Three-week-old C57BL/6 mice^[3]
Dosage:	0.05 or 0.5 mg/kg
Administration:	I.p.; daily for 2 or 10 weeks
Result:	The tibial length of mice increased in a dose-dependent manner.

Molecular Weight

277.28

Formula

C₁₆H₁₁N₃O₂

CAS No.

667463-82-3

Appearance

Solid

Color

Brown to red

SMILES

O/N=C1C2=C(C=CC=C2)NC\1=C3C4=C(C=CC=C4)NC\3=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (360.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.6065 mL	18.0323 mL	36.0646 mL
5 mM	0.7213 mL	3.6065 mL	7.2129 mL
10 mM	0.3606 mL	1.8032 mL	3.6065 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.02 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.10%

Select Batch:

Data Sheet (282 KB) SDS (604 KB)

COA (259 KB) LCMS (98 KB)

Handling Instructions (2659 KB)

References

[1]. Xie Y, et al. Indirubin-3'-oxime inhibits c-Jun NH2-terminal kinase: anti-apoptotic effect in cerebellar granule neurons. Neurosci Lett. 2004;367(3):355-359. [Content Brief]

[2]. Hu S, et al. Indirubin-3-Oxime Effectively Prevents 6OHDA-Induced Neurotoxicity in PC12 Cells via Activating MEF2D Through the Inhibition of GSK3β. J Mol Neurosci. 2015;57(4):561-570. [Content Brief]

[3]. Choi S, et al. Indirubin-3'-oxime stimulates chondrocyte maturation and longitudinal bone growth via activation of the Wnt/β-catenin pathway. Exp Mol Med. 2019;51(9):1-10. Published 2019 Sep 12. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.6065 mL	18.0323 mL	36.0646 mL	90.1616 mL
	5 mM	0.7213 mL	3.6065 mL	7.2129 mL	18.0323 mL
	10 mM	0.3606 mL	1.8032 mL	3.6065 mL	9.0162 mL
	15 mM	0.2404 mL	1.2022 mL	2.4043 mL	6.0108 mL
	20 mM	0.1803 mL	0.9016 mL	1.8032 mL	4.5081 mL
	25 mM	0.1443 mL	0.7213 mL	1.4426 mL	3.6065 mL
	30 mM	0.1202 mL	0.6011 mL	1.2022 mL	3.0054 mL
	40 mM	0.0902 mL	0.4508 mL	0.9016 mL	2.2540 mL
	50 mM	0.0721 mL	0.3606 mL	0.7213 mL	1.8032 mL
	60 mM	0.0601 mL	0.3005 mL	0.6011 mL	1.5027 mL
	80 mM	0.0451 mL	0.2254 mL	0.4508 mL	1.1270 mL
	100 mM	0.0361 mL	0.1803 mL	0.3606 mL	0.9016 mL

Indirubin-3′-oxime Related Classifications

Neurological Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Indirubin-3′-oxime (Synonyms: IDR3O; I3O)

Customer Review

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All CDK Isoform Specific Products:

View All GSK-3 Isoform Specific Products:

View All JNK Isoform Specific Products:

View All Wnt Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Indirubin-3′-oxime Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Indirubin-3′-oxime (Synonyms: IDR3O; I3O)

Customer Review

Indirubin-3′-oxime Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All CDK Isoform Specific Products:

View All GSK-3 Isoform Specific Products:

View All JNK Isoform Specific Products:

View All Wnt Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Indirubin-3′-oxime Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Indirubin-3′-oxime Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report